Development of an Optimised Losartan Potassium Press-Coated Tablets for Chronotherapeutic Drug Delivery by Latha, K et al.
Latha et al 
Trop J Pharm Res, October 2011;10(5): 551 
Tropical Journal of Pharmaceutical Research October 2011; 10 (5): 551-558 
© Pharmacotherapy Group,  
Faculty of Pharmacy, University of Benin,  
Benin City, 300001 Nigeria.  
All rights reserved. 
 






Development of an Optimised Losartan Potassium 
Press-Coated Tablets for Chronotherapeutic Drug 
Delivery 
 
K Latha*1, MU Uhumwangho2 SA Sunil3, MV Srikanth3 and KV Ramana 
Murthy3 
1 
G. Pulla Reddy College of Pharmacy, Mehidipatnam,Hyderabad,500 028, India, 
2
Department of Pharmaceutics and 
Pharmaceutical Technology, Faculty of Pharmacy, University of Benin, Benin City 300001, Nigeria, 
3
University 





Purpose: To develop an optimised press-coated tablets of losartan potassium using an admixture of a 
hydrophilic polymer, hydroxypropylmethylcellulose (HPMC) and microcrystalline cellulose (MCC) in 
order to achieve a predetermined lag time for chronotherapy. 
Methods: The press-coated tablets (PCT) containing losartan potassium in the inner core were 
prepared by compression-coating with HPMC 100KM alone and admixed with MCC as the outer layer in 
different ratios. The effect of the outer layer on the lag time of drug release was investigated. The 
parameters determined were tablet tensile strength, friability, drug content and in vitro dissolution. The 
optimised formulation was further characterized with Fourier-transform infrared spectroscopy (FTIR) and 
powder X-ray diffractometry (PXRD) to investigate any drug/excipient modifications/interactions.  
Results: The tensile strength values of all the PCT were between 1.12 and 1.23MNm-
2
 and friability 
was < 0.36 %. The release profile of the press-coated tablet exhibited a distinct lag time before burst 
release of losartan potassium. Lag time was dependent on the ratio of HPMC/MCC in the outer shell. 
The lag time was from 0.5 to 18.5 h and could be modulated as it decreased as the amount of MCC in 
the outer layer increased. There was no modification or chemical interaction between the drug and the 
excipient.  
Conclusion: Formulation LPP2, with HPMC/MCC of (30:70) in the outer shell and showing a 
predetermined lag time of 6 h prior to burst release of the drug from the press-coated tablet was taken 
as the optimized formulation.  
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INTRODUCTION 
 
Hypertension is a chronic disorder present in 
over 90 % of all patients with cardiovascular 
(CV) disease and is a major risk factor for CV 
disease which sometimes leads to sudden 
death [1,2]. Treatment of this disease 
condition occurring in the early hours is not 
convenient by using conventional immediate 
release dosage form. Hence, 
chronotherapeutic drug delivery system 
(ChDDS) may be useful for such patients 
since the drug is released at a predetermined 
lag time. Chronotherapeutics refers to a 
treatment method in which in vivo drug 
availability is timed to match the rhythms of 
disease, in order to optimize therapeutic 
outcomes and minimise side effects [3,4]. It is 
designed such that drug release is modulated 
in a manner that ensures that maximum 
concentration (Cmax) of the drug is reached at 
the maximum intensity of the disease 
condition. Cmax of the drug is normally 
reached within 1 - 2 h for many conventional 
dosage forms and this may not match with 
the maximum intensity of the disease state. 
Hence, for effective therapy, it is always 
advisable to provide maximum drug 
concentration at maximum intensity of 
disease condition. 
 
Losartan potassium is a highly specific, non-
peptide angiotensin II antagonist indicated for 
the treatment of hypertension [5]. It blocks 
the renin–angiotensin system by suppressing 
the effects of angiotensin II at its receptors 
[6], It is a weakly acidic yellowish white 
crystalline powder with a pKa of 4.9. 
Chemically, it is 2-n-butyl-4-chloro-5-
hydroxymethyl-1-[2_-(1H-tetrazol-5-yl)biphen 
ly l-4-yl)methyl]imidazole with a biological half 
life of 2-2.5 h [6,7]. The adult dose is 25 mg, 
50 mg and 100 mg once daily (based on 
requirement) for prophylaxis, normal 
treatment and severe conditions. 
 
Press-coated tablets (PCT) are formulations 
comprising of an inner core that contains the 
active pharmaceutical ingredient and 
surrounded by an outer layer of polymer 
and/or excipients that dissolves or 
disintegrates slowly to produce lag time. The 
advantages of this technique include low 
equipment cost, short processing time and 
reduced production steps.  It does not require 
the use of a large amount of organic solvents 
compared with the spray coating which needs 
a high amount of solvent for dissolving the 
drug or polymer used for coating, besides the 
solvents are often expensive and hazardous 
to the environment [8]. 
 
The purpose of the present study was to 
modulate the predetermined time lag of PCT 
of losartan potassium using an admixture of 
hydroxypropyl methylcellulose (HPMC) and 
microcrystalline cellulose (MCC) as excipient 






Losartan potassium was received as a gift 
from Ipca Laboratories Pvt. Ltd, Mumbai, 
India. Hydroxy propyl methyl cellulose HPMC 
100 KM (Aurbindo Pharma Ltd, Hyderabad, 
India), MCC, Croscarmellose sodium (CCS), 
Polylvinylpyrrolidone (PVP K30) were 
received free of charge from Aurbindo 
Pharma Ltd, Hyderabad, India and were used 
as diluent, disintegrant and binding agent, 
respectively. Talc and magnesium stearate 
(S.D. Fine Chemicals Ltd., Mumbai, India) 
were used as glidant and lubricant, 
respectively. All other reagents used were of 
analytical grade. Two different commercial 
immediate release formulations of losartan 
potassium tablets (CT) P1 and P2 were 
purchased from the market. Their 
manufacturing and expiring dates, and batch 
numbers were recorded. The manufacturing 
dates of Alsartan (P1) and Covance (P2) are 
May 2007 and August 2008, respectively, 
while their corresponding expiring dates are 
April 2010 and July 2011.  
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Preparation of an optimised core tablet 
(OCT) 
 
From preliminary studies in our laboratory, an 
optimized core tablet was formulated using 
various concentrations and different types of 
diluents, disintegrants and binders. The 
composition is shown in the footnote of Table 
1. The ingredients were then passed through 
a sieve of 710 µm aperture size, transferred 
to a poly bag and blended for 5 min. Talc and 
magnesium stearate, passed through a sieve 
of 500 µm aperture size before weighing, 
were added to the blend and mixed for 2 min. 
The resulting blend was compressed with a 
rotary compression machine (Model Riddhi, 
Ahmedabad, India) to form a 6 mm biconvex 
tablet. The mean weights of the tablets were 
106.5 ± 3.2 mg. 
 
Preparation of press-coated tablets (PCT). 
 
The HPMC 100KM and MCC were accurately 
weighed as required for a batch of 100 
tablets as per formulae given in Table 1. A 
solution of 7.5 % PVP in hydro alcoholic 
mixture of iso propyl alcohol and water in the 
ratio of 70:30 was used to wet mass the 
HPMC 100KM and MCC. The wet mass was 
pressed through a sieve of 710µm aperture 
size  and dried for 2 hrs at 45
0
C in a hot air 
oven (Tempo Instruments and equipments 
Pvt Ltd). The dried mass was again screened 
through a sieve of 500 µm aperture size.  
Talc and magnesium stearate were added to 
the dried granules and passed through a 
sieve of 500 µm aperture size and blended 
for 2 minutes. Half the amount of polymer 
granules was placed inside the die to make a 
powder bed. The core tablet was placed at 
the centre on the polymer bed while the 
remaining half of the polymer granules was 
filled into the die. The content was 
compressed at a constant compression force 
with a rotary compression machine (Model 
Riddhi, Ahmedabad) to form a bi convex 





Five tablets were placed in the drum of a 
friabilator (Electro labs, Model EF2, Mumbai, 
India) rotating at 25 rpm for 4 min. The 
percentage dust formed due to the impact 
was determined and taken as index of 
friability. The test was carried out in triplicate. 
 
Disintegration test (DT) 
 
The method described in the British 
Pharmacopoeia [9] was followed using water 
maintained at 37±2 °C as the disintegration 
fluid. Six tablets were placed in the 
disintegration apparatus (Electrolab, Model, 
ED-2L Mumbai, India)) for each 
determination. It was carried out in triplicate 
and the mean results reported. 
 
Determination of tablet tensile strength (T) 
 
This is the stress needed to fracture a tablet 
by diametral compression. It is given by Fell 
and Newton [10] as in Eq 1.  
 
T= 2P/πDt  ………………………………. (1)  
 
where P is the fracture load that causes 
tensile failure of a tablet of diameter D, and 
thickness t. The fracture load (kg) of ten 
tablets was determined individually with a 
Monsanto hardness tester (Tab Machines, 
Mumbai, India), using the procedure of Brook  
 
Table 1: Composition of the press-coated tablets (PCT) 
 
Ingredient (mg) LPP 1 LPP2 LPP 3 LPP4 LPP5 
HPMC 100 KM 0 30 50 70 100 
MCC 100 70 50 30 0 
 Note: Each tablet core contained losartan potassium (50 mg), Avicel (50 mg), CCS (2.5 mg), PVP K 30 (2.5 mg), 
magnesium stearate (0.5 mg), Talc (1mg) HPMC 100KM:MCC ratio in the outer coat layer LPP1 (0:100), LPP2 
(30:70), LPP3 (70:30), LPP4 (100:0).  
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and Marshal [11]. The mean values of the 
fracture loads were used to calculate T 
values for the various tablets. 
 
In vitro drug release studies 
 
OCT and two different CT formulations were 
subjected to in vitro drug release in 900 ml of 
6.8 pH
 
phosphate buffer for 90 min. while the 
PCT formulations were also subjected to in 
vitro drug release sequentially in two different 
suitable dissolution media to assess their 
ability to provide the desired lag time before 
drug release. USP Type I dissolution 
apparatus (Electrolab, Model TDT-08l, 
Mumbai, India) was used. The dissolution 
medium for the first 2 h was 900 ml of 0.1M 
HCl (pH 1.2) and continued in phosphate 
buffer (pH 6.8) for the next 22 h. The 
temperature of dissolution medium was 
maintained at 37 ± 0.2 °C and the basket was 
rotated at 50 rpm. An aliquot of 5 ml was 
withdrawn at predetermined time intervals 
and replaced with an equal volume of the 
fresh dissolution medium to maintain sink 
conditions. The samples were filtered through 
a 0.45 µm cellulose acetate filter and 
analyzed at λmax of 230 nm, for the 
percentage drug release using an Elico SL 
210 UV-Visible double beam 
spectrophotometer. One tablet was used for 
each determination and the experiment was 
performed in triplicates. 
 
Drug content determination 
 
In order to determine the content of losartan 
potassium, 5 tablets were weighed and 
crushed to fine powder. The powder 
equivalent to 50 mg of drug was weighed out, 
transferred to a 100 ml volumetric flask and 
made up the volume  with phosphate buffer 
(pH 6.8).The resulting solution was filtered 
and 1ml of it diluted to 10 ml with phosphate 
buffer. The absorbance of the resulting 
solution was measured at 230 nm using a 
spectrophotometer and the drug content was 
computed. 
Fourier transform infra red (FTIR) studies 
 
The FTIR spectrum of the different samples 
were recorded with an infra red spectrometer 
(Shimadzu, Model 84005, Japan) using 
potassium bromide discs prepared from 
powdered samples. The spectrum was 




Powder X-ray diffraction (PXRD) 
 
PXRD was performed using type XRD-7000 
diffractometer (Shimadzu, Japan). The 
samples were exposed to Cu Ka radiation at 
56 kV and 182 mA over the 2-theta range 






The data obtained were subjected to Student 
t-test to test for significance of difference 
between paired data and p > 0.05 was taken 
as significant. Origin 8 software package was 




Physicochemical parameters of the 
formulations 
 
The friability values (%) for OCT and the two 
CT formulations, were 0.42 ± 0.05 (OCT), 
0.51 ±0 .07 (P1) and 0.53 ± 0.05 (P2) 
respectively, while their corresponding tensile 
strength was 1.06 ± 1.2, 1.10 ± 1.36 and 1.10 
± 1.2 MNm
-2.
. DT for OCT and the two CT 
were 2.0 ± 0.02, 9.0 ± 0.4, and 8.5 ± 1.0 min, 
respectively, and their drug content 99.1 ± 
1.5, 99.3 ± 0.35 and 99.0 ± 0.13 %, 
respectively.  On the other hand, the friability 
(%) of PCT, i.e., LPP1 to LPP5, was 0.33 ± 
0.05, 0.30 ± 0.05, 0.35 ± 0.05, 0.36 ± 0.04 
and 0.32 ± 0.04; tensile strength 1.12 ± 0.23, 
1.23 ± 0.64, 1.23 ± 0.25, 1.12 ± 0.18 and 




and drug content 99.9 ± 
1.36, 99.58 ± 1.49, 99.86 ± 1.18, 99.78 ± 
1.18 and 99.5 ± 1.25 %.  
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Drug release profile of standard losartan 
potassium formulations 
 
The drug release profiles of the OCT and the 
two CT formulations are presented in Fig 1. 
The release parameters derived from the 
curves are shown in Table 2. It was observed 
that OCT showed comparable release profile 
with those of the two CT. For OCT and the 
two CT (P1 and P2) maximum release (m∞) 
was 93, 84 and 79 %, respectively while the 
time to attain maximum release (t∞) was the 
same for all the formulations (i.e., 45 min), 
However, the dissolution rate (m∞/t∞) was 
2.01, 1.87 and, 1.76 % min
-1
 for OCT, P1and 
P2, respectively. Overall, there was no 
significant difference between the release 



























Time (h)  
Fig 1:  Cumulative losartan potassium release 
from OCT (∆), P1   (◊), P2 () tablet formulations 
in phosphate buffer (pH 6.8). 
 
Table 2: Dissolution parameters {m∞ (%), t∞ (min), 
m∞ /t∞(%min
-1
)} for OCT and two CT (P1 and P2) 
 
Formulation OCT P1 P2 
m∞ (%) 93 84 79 
t∞(min) 45 45 45 
m∞ / t∞ (%min
-1
) 2.01 1.87 1.76 
 
Drug release profile of test PCT losartan 
potassium formulations 
 
The drug release profiles of the test PCT 
(LPP1 – LPP5) formulations of losartan 
potassium are shown in Fig 2. They indicate 
that losartan potassium release from the 
press-coated tablet exhibited a unique lag 
time before burst release.  Generally, lag time 
increased as the amount of HPMC100KM in 
the outer layer increased. For instance, lag 
time of the formulations (with ratios of 
HPMC100KM: MCC as the outer coat) was 
5.5, 9.5, 14.0 and 18.5 h for LPP2 (30:70), 
LPP3 (50:50) LPP4 (70:30) and LPP5 
(100:0), respectively. The longest time lag 
(18.5 h) was for losartan potassium when 
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Fig 2:  Cumulative losartan potassium release 
from LPP1 (◊), LPP2 (), LPP3 (∆), LPP4 (O), 
LPP5 (♦) tablet formulations in phosphate buffer 
(pH 6.8) 
 
FTIR spectra  
 
The spectra obtained are shown in Fig 3. All 
the characteristic peaks observed separately 
for both the drug and excipient (Fig 3a and b, 
respectively) remained unchanged in the 
optimised PCT formulation (Fig 3c).  
 
Powder x-ray diffraction  
 
The powder x-ray diffraction patterns of the 
drug and polymer (HPMC 100KM) as well as 
the optimized PCT are presented in Fig 4. 
Losartan potassium showed distinct 
characteristic crystalline peaks at 2θ angles 
of 11.5, 14.5, 19.5 and 24.2
0
 (Fig 4a). On the 
other hand, HPMC 100KM showed no 
characteristic peaks which indicates that it is 
amorphous (Fig 4b). These peaks remained 
unchanged in the optimized PCT formulation 
(Fig 4c).  
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Fig 3: FTIR spectra of (a) losartan potassium, (b) 




Physical properties of tablet  
 
Friability is a measure of the ability of the 
tablet to withstand abrasion during 
packaging, handling and transportation. The 
friability values for all the formulations (OCT, 
two CT and optimised PCT) met the British 
Pharmacopeia (BP) requirements [9].  
 
Drug release and lag time 
 
It is well known that tablet tensile strength 
can affect the release rate of drug [12]. 
Previously, Katikaneni et al had reported that 
increase in tensile strength is accompanied 
by a decrease in release rate, due to a 
decrease in tablet porosity [13]. However, 
since there is no significant difference (p > 
0.05) in tablet tensile strength among all the 
PCT formulations, it seems therefore that the 
lag time of losartan potassium release before 
burst release may be due to the varying  ratio 
of HPMC:MCC blend used as the outer layer. 
 
 (a) 
  (b) 
 (c) 
Fig 4: Powder x-ray diffraction pattern of  (a) 
losartan potassium, (b) HPMC 100KM  and  
(c) PCT formulation 
 
Oral controlled-release formulations are 
designed to modify drug release in order to 
optimize drug therapy and hence improve 
patient’s compliance. Of recent, researchers 
have focused on designing oral timed-release 
drug delivery systems for the treatment 
and/or management of diseases which follow 
circadian rhythm [14]. Hence, medications 
needed for the treatment and/or management 
of such disease conditions should be 
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administered at the necessary time to 
maintain a therapeutic blood level in the body 
system.  
 
MCC was admixed with HPMC100KM to 
modulate the lag time and hence control the 
disintegration of the PCT. Drug release from 
OCT which did not have the outer layer was 
complete within 45 min, since there was no 
barrier to delay dissolution. Hydroxypropyl 
methylcellulose (HPMC) forms a firm gel but 
does not hydrate quickly while MCC is a good 
disintegrant and acts by a wicking 
mechanism. Hence, the drug was 
immediately released from the tablet core 
after the rupture of the surrounding outer 
layer containing MCC alone and admixture of 
HPMC100KM and MCC. This could be due to 
the pressure build-up within the PCT. This 
pressure built up might be attributed to the 
influx of dissolution medium by wicking effect 
due to the presence of MCC in the outer 
layer. This suggests that MCC might possibly 
be acting as a pore-forming agent in the outer 
layer rather than as a disintegrant, thus 
enhancing the penetration of water before 
rupturing the surrounding outer layer. The 
reason for the prolonged lag time (18.5 h) for 
the PCT prepared with HPMC100KM alone 
as the outer shell might be attributed to the 
high gelling effect of HPMC100KM which 
prevented the rapid influx of fluid into the 
outer layer that could have caused the 
rupture of the PCT to bring about burst 
release. 
 
FTIR results ruled out the possibility of 
chemical interaction and complex formation 
between the losartan potassium and HPMC 
during the production process. Similarly, x-
ray diffractograms also showed that the 
crystalline nature of the drug was maintained 




The findings of this work indicate that the 
time lag of press-coated losartan potassium 
tablets can be modulated from 5.5 to 14 h 
when MCC was blended with HPMC 100KM 
in the outer layer of the tablet. Formulation 
LPP2 with a lag time of 6 h before burst 
release of the drug from the press-coated 
tablet was taken as the optimized 
formulation. Losartan potassium showed no 
observable physical and/or chemical 
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